What is PATH EX?
PATH EX is at the forefront of developing investigational extracorporeal blood cleansing devices designed for the diagnosis and treatment of sepsis. Their proprietary technology focuses on the selective removal of pathogens and endotoxins directly from the blood. Studies have demonstrated significant reductions in bacterial concentrations, positioning PATH EX's innovations as potentially transformative for critical care settings and infectious disease management, particularly in the immediate treatment of bacteremia. The company's work holds profound implications for improving patient outcomes in healthcare environments where rapid intervention is paramount.
How much funding has PATH EX raised?
PATH EX has raised a total of $5M across 1 funding round:
Other Financing Round
$5M
Other Financing Round (2025): $5M with participation from IAG Capital Partners, TMC Ventures, and Fitz Gate Ventures
Key Investors in PATH EX
IAG Capital Partners
IAG Capital Partners is a venture capital firm specializing in leading investment rounds from seed to Series C, operating from Charleston, SC, and London, UK. They focus on providing financial support to innovative companies at various stages of their development.
TMC Ventures
TMC Ventures specializes in carefully selected, evidence-based supplements for various health concerns, emphasizing ethical practices and customer value. They aim to support clients seeking natural health solutions and specific dietary needs.
Fitz Gate Ventures
Fitz Gate Ventures is an early-stage venture capital firm that leverages its 'Friends of Fitz' community to provide strategic advantages to its portfolio companies, with a particular emphasis on deeptech startups across the U.S.
What's next for PATH EX?
This substantial enterprise-level funding positions PATH EX for significant expansion and advancement. The capital injection is expected to accelerate the company's research and development efforts, potentially leading to broader clinical trials and regulatory submissions. The strategic investment signals a strong belief in PATH EX's technology to address critical unmet needs in sepsis management and pathogen removal. Future growth will likely involve scaling manufacturing capabilities, forging strategic partnerships within the healthcare sector, and further validating the clinical efficacy of their blood cleansing devices to establish a dominant market presence.
See full PATH EX company page
